Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Pooled result · Change in HbA1cResult — go to the resultWMD −0.53 % 95% CI −0.75 to −0.31Authors' conclusion
In this meta-analysis, the use of bexagliflozin was associated with improved clinical and laboratory measures in patients with T2DM compared with placebo, with a similar profile of side effects. These findings support the efficacy of bexagliflozin in the treatment of T2DM.
Study context
- Population
- Patients with T2D in placebo-controlled RCTs published up to 15 February 2023
- Participants
- 3,111 patients6 studies
- Comparison
- Bexagliflozin vs placebo
- Bexagliflozinn = 1,951
- Outcome
- Change in HbA1c
Methodological detailsplacebo-controlled
- Placebo-controlled
Pooled result
As reported in the abstract
WMD
−0.53 %
95% CI −0.75 to −0.31
Bexagliflozinvs Placebo
WMD −0.53 % (95% CI −0.75 to −0.31)
Further pooled results
| Outcome | WMD (mmol/L) (95% CI) | |
|---|---|---|
| FPG | −1.45 (−2.32 to −0.57) | |
| −3−2−101Difference, mmol/L (linear scale) |
| Outcome | WMD (mmHg) (95% CI) | |
|---|---|---|
| Systolic blood pressure | −4.66 (−6.41 to −2.92) | |
| Diastolic blood pressure | −2.12 (−3.94 to −0.30) | |
| −10−505Difference, mmHg (linear scale) |
| Outcome | WMD (kg) (95% CI) | |
|---|---|---|
| Body weight overall | −1.61 (−2.14 to −1.07) | |
| Body weight, subgroup BMI >25 kg/m² | −2.05 (−2.78 to −1.31) | |
| −4−202Difference, kg (linear scale) |
| Outcome | OR (95% CI) | |
|---|---|---|
| Achieved HbA1c < 7% | 1.94 (1.36–2.78) | |
| 0.20.5125Odds ratio (log scale) |
Safety
Side effects and all-cause mortality
- No significant differences between groups in hypoglycaemia, genital mycotic infection, UTI, diarrhoea, headache, nausea, polyuria, DKA or all-cause mortality
Original publication
Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 3 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →